CD274 and neoplasm: For PS0-1 patients with tumor cell PD-L1 expression ≥50%, the median OS for NSQ was 23.8 (17.7–29.3) and 27.3 (21.6-NA) months for monotherapy/combination therapy (n = 281/55), while the median OS for combination regimens for PD-L1 <1% and 1–49% was 18.6 (12.1–26.9) and 15.9 (10.8–26.7) months (NSQ; n = 65/87).